Yescar­ta goes to Chi­na as Fo­s­un Kite nabs his­toric first CAR-T OK

4 years ago
China
Cell/Gene Tx

With FDA fil­ing for key gene ther­a­py pushed back 6 months, uniQure opens the pock­et­book to re­fresh the pipeline

4 years ago
Deals
FDA+

Wood­cock de­fends Bio­gen's new Alzheimer's drug, says it has more sup­port­ive da­ta than many past ac­cel­er­at­ed ap­provals

4 years ago
FDA+

Black­stone throws $250M be­hind In­tel­lia-Cellex quest to com­bine CRISPR and con­trol­lable CAR-Ts

4 years ago
Deals

Con­sor­tium of 5 drug reg­u­la­tors plot path to in­crease har­mo­niza­tion through 2024

4 years ago
FDA+

New DARPA-like NIH agency preps for re­al­i­ty as E&C un­veils bi­par­ti­san Cures 2.0 draft bill

4 years ago
FDA+

Roche's Alzheimer's drug spurred bio­mark­er changes but no cog­ni­tive im­pact — pa­per; vTv out-li­cens­es for­mer lead ...

4 years ago
News Briefing

Covid-19 roundup: White House re­veals vac­cine do­na­tion plan; EU opts in for an­oth­er 150 mil­lion dos­es from Mod­er­na

4 years ago
Coronavirus

Neu­rona Ther­a­peu­tics is dash­ing to the clin­ic with its cell ther­a­py for epilep­sy — but first, an­oth­er ven­ture round

4 years ago
Financing
R&D

A Re­cur­sion vet­er­an is map­ping plant life to chart a course to new ther­a­pies — and in­vestors like what they see

4 years ago
Financing
AI

Top an­a­lyst chimes in on bub­bling de­bate about Glax­o­SmithK­line's fu­ture with a clear mes­sage: Let your £40B vac­cines ...

4 years ago
Pharma

Top Wyden pri­or­i­ty for drug price re­forms: Medicare ne­go­ti­a­tions

4 years ago
Pharma

Al­fasig­ma snares EU rights to blood clot­ting an­ti­body on the hunt for pa­tients tak­ing As­traZeneca's Bril­in­ta

4 years ago
Deals

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

4 years ago
R&D
Pharma

Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

4 years ago
Financing

The Covid-19 trans­genic cow an­ti­body start­up goes pub­lic in $325M SPAC merg­er

4 years ago
Financing

They went from dai­ly to once every two months. But how much longer act­ing can HIV meds be? Vi­iV en­lists Halozyme's ...

4 years ago
Deals

Bio­gen's new Alzheimer's drug serves as a ral­ly­ing cry for drug pric­ing re­forms

4 years ago
Pharma
FDA+

On the hunt for the next Mod­er­na, in­vestors have pumped 'plat­form plays' with cash. Can any­thing slow the run­away ...

4 years ago
Financing
In Focus

The dig­i­tal health field con­tin­ues to boom as Soft­Bank-backed start­up hits uni­corn sta­tus in SPAC re­verse merg­er

4 years ago
Financing
Deals

With a new $255M megaround in hand, Alex Zha­voronkov has big plans for In­sil­i­co. Are they fea­si­ble?

4 years ago
Financing
AI

South African con­sor­tium es­tab­lish­es mR­NA tech trans­fer hub to get vac­cines to a re­gion of­ten over­looked

4 years ago
Coronavirus
Manufacturing

South Ko­re­an vac­cine mak­er pumps up its pro­duc­tion ca­pac­i­ty as Covid-19 de­mand holds steady

4 years ago
Coronavirus
Manufacturing

As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin ...

4 years ago
News Briefing
First page Previous page 677678679680681682683 Next page Last page
A service from the Financial Times